Table 2. Efficiency of the three methods tested for KRAS mutation analysis on FFPE-DNA samples from the diagnostic group A and the unfavorable control group B.

	eligible		informative
KRAS-TMGB	210		209	99,5%
group A	135		135	100%
group B	75		74	98,7%
fragmentation (≤200 bp)	108		107	99,1%
Cycle sequencing	129/210*	61,5%	111/210	52,8%
group A	129/135	95,5%	111/135	82,2%
group B	0/75		na	na
fragmentation (≤200 bp)	7/108	6,5%	2/108	1,9%
Therascreen KRAS	95		65	68,4%
group A	29		28	96,6%
group B	66		37	56,1%
fragmentation (≤200 bp)	81		51	62,9%

* =  samples were eligible for sequencing when the corresponding PCR product was visualized upon agarose gel electrophoresis.

na  =  not applicable.